CY1125885T1 - Τροποποιημενο πολυπεπτιδιο παραγοντα ix, οι χρησεις του και μια μεθοδος για την παραγωγη του - Google Patents

Τροποποιημενο πολυπεπτιδιο παραγοντα ix, οι χρησεις του και μια μεθοδος για την παραγωγη του

Info

Publication number
CY1125885T1
CY1125885T1 CY20231100138T CY231100138T CY1125885T1 CY 1125885 T1 CY1125885 T1 CY 1125885T1 CY 20231100138 T CY20231100138 T CY 20231100138T CY 231100138 T CY231100138 T CY 231100138T CY 1125885 T1 CY1125885 T1 CY 1125885T1
Authority
CY
Cyprus
Prior art keywords
polypeptide
fix polypeptide
modified fix
production
modified factor
Prior art date
Application number
CY20231100138T
Other languages
English (en)
Inventor
Paolo Simioni
Original Assignee
Uniqure Biopharma B.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41397565&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1125885(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from ITBO2008A000564A external-priority patent/IT1394177B1/it
Priority claimed from ITBO2009A000275A external-priority patent/IT1395980B1/it
Application filed by Uniqure Biopharma B.V. filed Critical Uniqure Biopharma B.V.
Publication of CY1125885T1 publication Critical patent/CY1125885T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/644—Coagulation factor IXa (3.4.21.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21022—Coagulation factor IXa (3.4.21.22)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Στο παρόν κείμενο περιλαμβάνονται ένα τροποποιημένο πολυπεπτίδιο FIX (παράγοντας IX) που περιλαμβάνει λευκίνη, κυστεΐνη, ασπαρτικό οξύ, γλουταμικό οξύ, ιστιδίνη, λυσίνη, ασπαραγίνη, γλουταμίνη ή τυροσίνη στη θέση 338 · φαρμακευτικά σκευάσματα που περιέχουν το εν λόγω τροποποιημένο πολυπεπτίδιο FIX · μια νουκλεοτιδική αλληλουχία που κωδικοποιεί το τροποποιημένο πολυπεπτίδιο FIX · και μια μέθοδο για την παραγωγή του τροποποιημένου πολυπεπτιδίου FIX.
CY20231100138T 2008-09-15 2023-03-14 Τροποποιημενο πολυπεπτιδιο παραγοντα ix, οι χρησεις του και μια μεθοδος για την παραγωγη του CY1125885T1 (el)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
ITBO2008A000564A IT1394177B1 (it) 2008-09-15 2008-09-15 Polipeptide fattore ix modificato, sue utilizzazioni e metodo per la sua produzione
ITBO2009A000275A IT1395980B1 (it) 2009-05-06 2009-05-06 Polipeptide fattore ix modificato, sue utilizzazioni e metodo per la sua produzione
PCT/EP2009/061935 WO2010029178A1 (en) 2008-09-15 2009-09-15 Factor ix polypeptide mutant, its uses and a method for its production
EP17175191.0A EP3252157A1 (en) 2008-09-15 2009-09-15 Factor ix polypeptide mutant, its uses and a method for its production
EP09748260.8A EP2337849B1 (en) 2008-09-15 2009-09-15 Factor ix polypeptide mutant, its uses and a method for its production

Publications (1)

Publication Number Publication Date
CY1125885T1 true CY1125885T1 (el) 2024-02-16

Family

ID=41397565

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20231100138T CY1125885T1 (el) 2008-09-15 2023-03-14 Τροποποιημενο πολυπεπτιδιο παραγοντα ix, οι χρησεις του και μια μεθοδος για την παραγωγη του
CY2023016C CY2023016I2 (el) 2008-09-15 2023-07-27 Τροποποιημενο πολυπεπτιδιο παραγοντα ix, οι χρησεις του και μια μεθοδος για την παραγωγη του

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY2023016C CY2023016I2 (el) 2008-09-15 2023-07-27 Τροποποιημενο πολυπεπτιδιο παραγοντα ix, οι χρησεις του και μια μεθοδος για την παραγωγη του

Country Status (18)

Country Link
US (11) US9249405B2 (el)
EP (5) EP2337849B1 (el)
CA (1) CA2737094C (el)
CY (2) CY1125885T1 (el)
DK (2) DK3581650T3 (el)
ES (2) ES2940323T3 (el)
FI (2) FI3581650T3 (el)
FR (1) FR23C1028I1 (el)
HK (1) HK1244507A1 (el)
HR (2) HRP20230259T1 (el)
HU (2) HUE061345T2 (el)
LT (2) LT3581650T (el)
NO (1) NO2023029I1 (el)
PL (3) PL2337849T3 (el)
PT (1) PT3581650T (el)
SI (1) SI3581650T1 (el)
TR (1) TR201813067T4 (el)
WO (1) WO2010029178A1 (el)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI3581650T3 (fi) 2008-09-15 2023-03-23 Uniqure Biopharma B V IX-tekijän polypeptidimutantti, sen käyttöjä ja menetelmä sen valmistamiseksi
TWI557135B (zh) 2010-11-03 2016-11-11 介控生化科技公司 經修飾之第九因子多胜肽及其用途
JP6363600B2 (ja) 2012-07-25 2018-07-25 カタリスト・バイオサイエンシーズ・インコーポレイテッドＣａｔａｌｙｓｔ Ｂｉｏｓｃｉｅｎｃｅｓ， Ｉｎｃ． 修飾第ｘ因子ポリペプチドおよびその使用
HRP20231183T1 (hr) 2013-02-15 2024-01-05 Bioverativ Therapeutics Inc. Optimizirani gen faktora viii
US11008561B2 (en) 2014-06-30 2021-05-18 Bioverativ Therapeutics Inc. Optimized factor IX gene
GB201420139D0 (en) 2014-11-12 2014-12-24 Ucl Business Plc Factor IX gene therapy
CN108138159A (zh) * 2015-06-23 2018-06-08 费城儿童医院 经修饰的因子ix、以及用于基因转移到细胞、器官和组织的组合物、方法和用途
EP3411478B1 (en) 2016-02-01 2022-06-08 Bioverativ Therapeutics Inc. Optimized factor viii genes
EP3491008A2 (en) 2016-07-26 2019-06-05 BioMarin Pharmaceutical Inc. Novel adeno-associated virus capsid proteins
CN106497949A (zh) * 2016-10-14 2017-03-15 上海交通大学医学院附属瑞金医院 一种高活性凝血因子ix突变体、重组蛋白与融合蛋白的制备与应用
CN110945127B (zh) 2017-05-22 2024-07-12 武田药品工业株式会社 用于血友病b的基因疗法的编码具有增加的表达的重组fix的病毒载体
JP2020526203A (ja) 2017-07-10 2020-08-31 ユニキュアー アイピー ビー．ブイ． ヒトにおけるａａｖ遺伝子療法のための手段及び方法
US11491212B1 (en) 2017-09-27 2022-11-08 Catalyst Biosciences, Inc. Subcutaneous administration of modified factor IX polypeptides and treatment of hemophilia B
KR20210008501A (ko) 2018-05-09 2021-01-22 바이오마린 파머수티컬 인크. 페닐케톤뇨증을 치료하는 방법
TW202005978A (zh) 2018-05-14 2020-02-01 美商拜奧馬林製藥公司 新穎肝靶向腺相關病毒載體
JP2021523198A (ja) 2018-05-14 2021-09-02 ビオマリン プハルマセウトイカル インコーポレイテッド 幼若対象におけるａａｖベクターの安定的発現
US10842885B2 (en) 2018-08-20 2020-11-24 Ucl Business Ltd Factor IX encoding nucleotides
BR112021002998A2 (pt) * 2018-08-20 2021-05-11 Ucl Business Ltd polinucleotídeos, partícula viral e composição
UY38389A (es) * 2018-09-27 2020-04-30 Sigilon Therapeutics Inc Dispositivos implantables para terapia celular y métodos relacionados
WO2021154414A2 (en) 2020-01-29 2021-08-05 Catalyst Biosciences, Inc. Gene therapy for hemophilia b with a chimeric aav capsid vector encoding modified factor ix polypeptides
US20240293516A1 (en) * 2021-07-01 2024-09-05 CSL Behring Lengnau AG Factor ix subcutaneous administration with enhanced safety

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5171569A (en) 1985-03-15 1992-12-15 National Research Development Corporation Factor IX preparations uncontaminated by plasma components or pox virus
US5583107A (en) 1990-09-04 1996-12-10 Cor Therapeutics, Inc. Agents affecting thrombosis and hemostasis
US5223408A (en) 1991-07-11 1993-06-29 Genentech, Inc. Method for making variant secreted proteins with altered properties
GB9408717D0 (en) 1994-05-03 1994-06-22 Biotech & Biolog Scien Res DNA sequences
US6227618B1 (en) 1996-02-23 2001-05-08 Schukra Usa, Inc. Cable attachment for a lumbar support
WO1997047737A1 (de) 1996-06-11 1997-12-18 Boehringer Mannheim Gmbh Rekombinante blutgerinnungsproteasen
US6315995B1 (en) 1996-09-27 2001-11-13 The Trustees Of Columbia University In The City Of New York Methods for treating an ischemic disorder and improving stroke outcome
CA2280700A1 (en) 1997-02-14 1998-08-20 American Red Cross Expression of active human factor ix in mammary tissue of transgenic animals
US6531298B2 (en) 1997-07-21 2003-03-11 The University Of North Carolina At Chapel Hill Factor IX antihemophilic factor with increased clotting activity
US6200560B1 (en) * 1998-10-20 2001-03-13 Avigen, Inc. Adeno-associated virus vectors for expression of factor VIII by target cells
US7109170B2 (en) 1999-06-16 2006-09-19 Saint Louis University Region of factor IXa protease domain that interacts with factor VIIIa and methods therefor
AU2001249389A1 (en) 2000-03-22 2001-10-03 The Children's Hospital Of Philadelphia Modified blood clotting factors and methods of use
US7125841B2 (en) 2000-11-14 2006-10-24 The University Of Texas Systems Mutant human factor IX with an increased resistance to inhibition by heparin
US20040133930A1 (en) 2002-03-11 2004-07-08 Cooper Julian D. Production of high levels of transgenic factor ix without gene rescue, and its therapeutic uses
WO2002096454A1 (en) 2001-05-31 2002-12-05 D. Collen Research Foundation Vzw Recombinant molecules with reduced immunogenicity, methods and intermediates for obtaining them and their use in pharmaceutical compositions and diagnostic tools
PL369065A1 (en) 2001-09-04 2005-04-18 Merck Patent Gmbh Modified factor ix
US7179617B2 (en) * 2001-10-10 2007-02-20 Neose Technologies, Inc. Factor IX: remolding and glycoconjugation of Factor IX
US20040009151A1 (en) 2002-04-04 2004-01-15 Kay Mark A. Methods for delivering recombinant adeno-associated virus virions to the liver of a mammal
WO2003089612A2 (en) * 2002-04-17 2003-10-30 University Of Florida Research Foundation, Inc. IMPROVED rAAV VECTORS
US20040146938A1 (en) 2002-10-02 2004-07-29 Jack Nguyen Methods of generating and screening for proteases with altered specificity
ATE490307T1 (de) * 2003-05-21 2010-12-15 Genzyme Corp Verfahren zur herstellung von präparationen rekombinanter aav-virionen, die weitgehend frei von leeren capsiden sind
US20060040856A1 (en) 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
GB0329681D0 (en) 2003-12-23 2004-01-28 Delta Biotechnology Ltd Gene expression technique
DE602005021509D1 (de) 2004-08-17 2010-07-08 Csl Behring Gmbh Modifizierte vitamin-k-abhängige polypeptide
EP1627771B1 (de) 2004-08-19 2008-10-15 Gerd Bär Hubladebühne mit querverschiebbarem Verbindungsrohr
WO2006031226A1 (en) 2004-09-13 2006-03-23 Saint Louis University Region of factor ixa protease domain that interacts with factor viiia and methods therefor
DK1804839T3 (da) * 2004-09-22 2012-04-10 St Jude Childrens Res Hospital Forbedret ekspression af faktor ix i genterapivektorer
US7998930B2 (en) 2004-11-04 2011-08-16 Hanall Biopharma Co., Ltd. Modified growth hormones
NZ555830A (en) 2004-12-15 2009-01-31 Univ North Carolina Chimeric vectors
WO2007047995A2 (en) 2005-10-21 2007-04-26 Catalyst Biosciences, Inc. Modified proteases that inhibit complement activation
WO2007059473A2 (en) * 2005-11-12 2007-05-24 Introgen Therapeutics, Inc. Methods for the production and purification of adenoviral vectors
WO2007075976A2 (en) 2005-12-21 2007-07-05 Inspiration Biopharmaceuticals, Inc. Method of producing biologically active vitamin k dependent proteins by recombinant methods
US7867484B2 (en) 2006-01-27 2011-01-11 University Of North Carolina At Chapel Hill Heparin and heparan sulfate binding chimeric vectors
EP1991257B1 (en) * 2006-03-07 2015-05-06 Baxter International Inc. Highly phosphorylated and sulfated recombinant factor ix
WO2007110231A2 (en) 2006-03-28 2007-10-04 Nautilus Biotech, S.A. MODIFIED INTERFERON-β (IFN-β) POLYPEPTIDES
US7588772B2 (en) * 2006-03-30 2009-09-15 Board Of Trustees Of The Leland Stamford Junior University AAV capsid library and AAV capsid proteins
BRPI0710671B8 (pt) * 2006-04-07 2021-05-25 Univ Texas uso de um vetor de bacteriofágo viral adenoassociado (aavp) terapêutico para a fabricação de um medicamento para o tratamento e profilaxia de uma doença hiperproliferativa
MX2008014685A (es) 2006-05-24 2008-11-27 Novo Nordisk Healthcare Ag Analogos de factor ix con semivida prolongada in vivo.
US20070280906A1 (en) * 2006-06-03 2007-12-06 Ognjen Petras Method to generate mirrored adenoassociated viral vectors
US8198421B2 (en) 2006-06-19 2012-06-12 Asklepios Biopharmaceutical, Inc. Modified factor VIII and factor IX genes and vectors for gene therapy
EP2084274A2 (en) * 2006-06-19 2009-08-05 Nautilus Technology LLC Modified coagulation factor ix polypeptides and use thereof for treatment
US7700734B2 (en) 2007-01-09 2010-04-20 Shu-Wha Lin Recombinant human factor IX and use thereof
AU2008209985A1 (en) 2007-02-01 2008-08-07 Baxter Healthcare S.A. Improved fix-mutant proteins for hemophilia B treatment
WO2008119815A1 (en) 2007-04-02 2008-10-09 Novo Nordisk A/S Subcutaneous administration of coagulation factor ix
US20100137211A1 (en) 2007-04-11 2010-06-03 Monahan Paul E Methods and compositions for intra-articular coagulation proteins
US20080260820A1 (en) 2007-04-19 2008-10-23 Gilles Borrelly Oral dosage formulations of protease-resistant polypeptides
BRPI0705943A2 (pt) 2007-04-19 2008-12-09 Nautilus Biotech formulaÇÕes de dosagem oral de polipeptÍdeos resistentes À protease e usos das mesmas para tratamento
US20090030072A1 (en) 2007-07-03 2009-01-29 Sucampo Ag Pharmaceutical combination of opioid and prostaglandin compound
US20110154516A1 (en) 2007-10-15 2011-06-23 Stafford Darrel W Human factor ix variants with an extended half life
SG189790A1 (en) * 2008-04-16 2013-05-31 Bayer Healthcare Llc Modified factor ix polypeptides and uses thereof
WO2009140015A2 (en) 2008-04-16 2009-11-19 Bayer Healthcare Llc Site-directed modification of factor ix
US20110137011A1 (en) 2008-04-21 2011-06-09 Novo Nordisk A/S Hyperglycosylated human coagulation factor ix
EP2149603A1 (en) 2008-07-28 2010-02-03 DRK-Blutspendedienst Baden-Württemberg-Hessen gGmbH Factor IX variants with clotting activity in absence of their cofactor and their use for treating bleeding disorders
FI3581650T3 (fi) 2008-09-15 2023-03-23 Uniqure Biopharma B V IX-tekijän polypeptidimutantti, sen käyttöjä ja menetelmä sen valmistamiseksi
AU2010266065B2 (en) 2009-06-25 2016-01-14 The University Of North Carolina At Chapel Hill Chimeric Factor VII molecules
PE20121643A1 (es) 2009-07-31 2012-11-25 Bayer Healthcare Llc Polipeptidos del factor ix modificados y usos de los mismos
TWI557135B (zh) 2010-11-03 2016-11-11 介控生化科技公司 經修飾之第九因子多胜肽及其用途
EP3513802B1 (en) 2012-10-26 2023-11-29 Vrije Universiteit Brussel Vector for liver-directed gene therapy of hemophilia and methods and use thereof
EP2881463A1 (en) 2013-12-09 2015-06-10 DRK-Blutspendedienst Baden-Württemberg-Hessen gGmbH Factor IX variants with clotting activity in absence of their cofactor and/or with increased F.IX clotting activity and their use for treating bleeding disorders
AU2016232146B2 (en) 2015-03-17 2021-11-04 Vrije Universiteit Brussel Optimized liver-specific expression systems for FVIII and FIX
CN108138159A (zh) 2015-06-23 2018-06-08 费城儿童医院 经修饰的因子ix、以及用于基因转移到细胞、器官和组织的组合物、方法和用途
UA126016C2 (uk) 2015-08-03 2022-08-03 Біовератів Терапеутікс Інк. Злитий білок фактора іх

Also Published As

Publication number Publication date
US20180258413A1 (en) 2018-09-13
FIC20230026I1 (fi) 2023-07-25
EP4032979B1 (en) 2024-05-01
EP4032979A1 (en) 2022-07-27
ES2687038T3 (es) 2018-10-23
US20200199564A1 (en) 2020-06-25
HUE061345T2 (hu) 2023-06-28
CA2737094A1 (en) 2010-03-18
NO2023029I1 (no) 2023-07-31
US20220090042A1 (en) 2022-03-24
US10465180B2 (en) 2019-11-05
EP2337849A1 (en) 2011-06-29
FR23C1028I1 (fr) 2023-10-06
EP4219547A3 (en) 2023-10-18
EP3581650A2 (en) 2019-12-18
US20200231958A1 (en) 2020-07-23
HUS2300024I1 (hu) 2023-08-28
EP3252157A1 (en) 2017-12-06
HRP20181442T1 (hr) 2018-12-14
DK2337849T3 (en) 2018-10-01
DK3581650T3 (da) 2023-03-13
LTPA2023521I1 (el) 2023-08-25
EP4032979C0 (en) 2024-05-01
HRP20230259T1 (hr) 2023-04-28
CA2737094C (en) 2018-02-20
PT3581650T (pt) 2023-03-08
CY2023016I1 (el) 2024-02-16
EP3581650A3 (en) 2020-03-25
FI3581650T3 (fi) 2023-03-23
CY2023016I2 (el) 2024-02-16
CA2737094F (en) 2010-03-18
US20160122740A1 (en) 2016-05-05
LT3581650T (lt) 2023-05-10
SI3581650T1 (sl) 2023-06-30
EP4219547A2 (en) 2023-08-02
HK1244507A1 (zh) 2018-08-10
ES2940323T3 (es) 2023-05-05
EP3581650B1 (en) 2022-12-28
WO2010029178A1 (en) 2010-03-18
TR201813067T4 (tr) 2018-09-21
US20220002702A1 (en) 2022-01-06
PL2337849T3 (pl) 2018-11-30
US20210238573A1 (en) 2021-08-05
US20210214704A1 (en) 2021-07-15
US9982248B2 (en) 2018-05-29
US20170355973A1 (en) 2017-12-14
PL4032979T3 (pl) 2024-09-30
US9249405B2 (en) 2016-02-02
EP2337849B1 (en) 2018-06-13
US20110244550A1 (en) 2011-10-06
US20200190498A1 (en) 2020-06-18
PL3581650T3 (pl) 2023-05-22

Similar Documents

Publication Publication Date Title
CY1125885T1 (el) Τροποποιημενο πολυπεπτιδιο παραγοντα ix, οι χρησεις του και μια μεθοδος για την παραγωγη του
CY1118980T1 (el) Στερεες μορφες ν-[2,4-δις(1,1-διμεθυλαιθυλ)-5-υδροξυφαινυλ]-1,4-διυδρο-4-οξοκινολινο-3-καρβοξαμιδιου
CY1112402T1 (el) Ενισχυτες υποδοχεων γλουταμικου
ATE526318T1 (de) Farnesoid-x-rezeptor-agonisten
NO20063624L (no) FC region varianter
EA200700255A1 (ru) Новый карбамилированный еро и способ его получения
CY1109888T1 (el) Προφαρμακα των ενωσεων 2,4-πυριμιδινδιαμινης και οι χρησεις αυτων
CY1112511T1 (el) Κρυσταλλικη στερεα βαση ρασαγιλινης (rasagiline)
ATE404225T1 (de) Radiofluorierte peptide
BRPI0515649B8 (pt) Processo para preparação de composições de anticorpo monoclonal altamente concentradas
CY1114504T1 (el) Συνθεσεις τιγεκυκλινης και μεθοδοι παρασκευης
CY1118180T1 (el) Μεθοδος για παρασκευη στερεας φαρμακευτικης συνθεσης
SMT201300093B (it) Formulazioni di vwf ricombinante liofilizzate
CY1111225T1 (el) Νεα πεπτιδια ως αναστολεις πρωτεασης νs3-σερινης ιου ηπατiτιδας c
SE0301010D0 (sv) Novel compounds
EA201270758A1 (ru) Мутанты fgf21 и их применение
BRPI0606687A2 (pt) composições nutracêuticas
NO20076687L (no) Oral doseringsform
SE0301009D0 (sv) Novel compounds
CY1109916T1 (el) Βενζιμιδαζολο-θειοφαινικες ενωσεις ως plk αναστολεις
EA201000327A1 (ru) Белок
CY1113257T1 (el) Παραγωγα βενζυλοπιπεραζινης τα οποια ειναι χρησιμα στη θεραπεια γαστρεντερικων διαταραχων
EA200601596A1 (ru) Улучшенный состав 6-меркаптопурина
EA200702543A1 (ru) Циклопентадиенильно-флуоренильные лиганды с углеродными мостиками
DE602005019063D1 (de) Verfahren zur herstellung von substanzen